|
1
|
Wang HY, Chang YL, To KF, Hwang JS, Mai
HQ, Feng YF, Chang ET, Wang CP, Kam MK, Cheah SL, et al: A new
prognostic histopathologic classification of nasopharyngeal
carcinoma. Chin J Cancer. 35:412016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chua MLK, Wee JTS, Hui EP and Chan ATC:
Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016. View Article : Google Scholar
|
|
3
|
Chen YP, Chan ATC, Le QT, Blanchard P, Sun
Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019.
View Article : Google Scholar
|
|
4
|
Filho AM, Laversanne M, Ferlay J, Colombet
M, Piñeros M, Znaor A, Parkin DM, Soerjomataram I and Bray F: The
GLOBOCAN 2022 cancer estimates: Data sources, methods, and a
snapshot of the cancer burden worldwide. Int J Cancer.
156:1336–1346. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jen CW, Tsai YC, Wu JS, Chen PL, Yen JH,
Chuang WK and Cheng SHC: Prognostic classification for patients
with nasopharyngeal carcinoma based on American Joint Committee on
cancer staging system T and N categories. Ther Radiol Oncol.
4:22020. View Article : Google Scholar
|
|
6
|
Zhang L, Huang Y, Hong S, Yang Y, Yu G,
Jia J, Peng P, Wu X, Lin Q, Xi X, et al: Gemcitabine plus cisplatin
versus fluorouracil plus cisplatin in recurrent or metastatic
nasopharyngeal carcinoma: A multicentre, randomised, open-label,
phase 3 trial. Lancet. 388:1883–1892. 2016. View Article : Google Scholar
|
|
7
|
Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie
A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, et al:
Management of locally recurrent nasopharyngeal carcinoma. Cancer
Treat Rev. 79:1018902019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bossi P, Chan AT, Licitra L, Trama A,
Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J,
et al: Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice
guidelines for diagnosis, treatment and follow-up†. Ann Oncol.
32:452–465. 2021. View Article : Google Scholar
|
|
9
|
Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia
J, Wu X, Huang Y, Yang Y, Lin Q, et al: Gemcitabine plus cisplatin
versus fluorouracil plus cisplatin as first-line therapy for
recurrent or metastatic nasopharyngeal carcinoma: Final overall
survival analysis of GEM20110714 phase III study. J Clin Oncol.
39:3273–3282. 2021. View Article : Google Scholar
|
|
10
|
Chen P, Liu B, Xia X, Huang P and Zhao J:
Current progress in immunotherapy of nasopharyngeal carcinoma. Am J
Cancer Res. 13:1140–1147. 2023.PubMed/NCBI
|
|
11
|
Liu X, Shen H, Zhang L, Huang W, Zhang S
and Zhang B: Immunotherapy for recurrent or metastatic
nasopharyngeal carcinoma. NPJ Precis Oncol. 8:1012024. View Article : Google Scholar
|
|
12
|
Kang Y, He W, Ren C, Qiao J, Guo Q, Hu J,
Xu H, Jiang X and Wang L: Advances in targeted therapy mainly based
on signal pathways for nasopharyngeal carcinoma. Signal Transduct
Target Ther. 5:2452020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang Y, He W, Ren C, Qiao J, Guo Q, Hu J,
Xu H, Jiang X and Wang L: Correction: Advances in targeted therapy
mainly based on signal pathways for nasopharyngeal carcinoma.
Signal Transduct Target Ther. 5:2652020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim J, Lee Y, Kim S and Park JC: Novel
therapeutic development for nasopharyngeal carcinoma. Curr Oncol.
32:4792025. View Article : Google Scholar
|
|
15
|
Morad G, Helmink BA, Sharma P and Wargo
JA: Hallmarks of response, resistance, and toxicity to immune
checkpoint blockade. Cell. 184:5309–5337. 2021. View Article : Google Scholar
|
|
16
|
Liu SL, Li XY, Yang JH, Wen DX, Guo SS,
Liu LT, Li YF, Luo MJ, Xie SY, Liang YJ, et al: Neoadjuvant and
adjuvant toripalimab for locoregionally advanced nasopharyngeal
carcinoma: A randomised, single-centre, double-blind,
placebo-controlled, phase 2 trial. Lancet Oncol. 25:1563–1575.
2024. View Article : Google Scholar
|
|
17
|
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen
J, Li J, Shi Y, Jin F, Xu R, et al: Toripalimab plus chemotherapy
for recurrent or metastatic nasopharyngeal carcinoma: The
JUPITER-02 randomized clinical trial. JAMA. 330:1961–1970. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou
T, Shen L, Wu H, Lang J, et al: Camrelizumab versus placebo in
combination with gemcitabine and cisplatin as first-line treatment
for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st):
A multicentre, randomised, double-blind, phase 3 trial. Lancet
Oncol. 22:1162–1174. 2021. View Article : Google Scholar
|
|
19
|
Liang YL, Liu X, Shen LF, Hu GY, Zou GR,
Zhang N, Chen CB, Chen XZ, Zhu XD, Yuan YW, et al: Adjuvant PD-1
blockade with camrelizumab for nasopharyngeal carcinoma: The DIPPER
randomized clinical trial. JAMA. 333:1589–1598. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee A and Keam SJ: Tislelizumab: First
approval. Drugs. 80:617–624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen
N, Chen X, Sun Y, He X, Hu C, et al: Tislelizumab plus chemotherapy
as first-line treatment for recurrent or metastatic nasopharyngeal
cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell.
41:1061–1072.e4. 2023. View Article : Google Scholar
|
|
22
|
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang
L, Wang B, Sun G, Ji Y, Cao G, et al: Sintilimab versus placebo in
combination with chemotherapy as first line treatment for locally
advanced or metastatic oesophageal squamous cell carcinoma
(ORIENT-15): Multicentre, randomised, double blind, phase 3 trial.
BMJ. 377:e0687142022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Zhang Y, Yang KY, Zhang N, Jin F,
Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, et al:
Induction-concurrent chemoradiotherapy with or without sintilimab
in patients with locoregionally advanced nasopharyngeal carcinoma
in China (CONTINUUM): A multicentre, open-label, parallel-group,
randomised, controlled, phase 3 trial. Lancet. 403:2720–2731. 2024.
View Article : Google Scholar
|
|
24
|
Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW,
Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al:
Antitumor activity of nivolumab in recurrent and metastatic
nasopharyngeal carcinoma: An international, multicenter study of
the Mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol.
36:1412–1418. 2018. View Article : Google Scholar
|
|
25
|
Jung HA, Park KU, Cho S, Lim J, Lee KW,
Hong MH, Yun T, An HJ, Park WY, Pereira S, et al: A phase II study
of nivolumab plus gemcitabine in patients with recurrent or
metastatic nasopharyngeal carcinoma (KCSG HN17-11). Clin Cancer
Res. 28:4240–4247. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu C, Zhou GQ, Li WF, Hu DS, Chen XZ, Lin
SJ, Jin F, Huang XQ, Peng G, Huang J, et al: Nivolumab combined
with induction chemotherapy and radiotherapy in nasopharyngeal
carcinoma: A multicenter phase 2 PLATINUM trial. Cancer Cell.
43:925–936.e4. 2025. View Article : Google Scholar
|
|
27
|
Hsu C, Lee SH, Ejadi S, Even C, Cohen RB,
Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et
al: Safety and antitumor activity of pembrolizumab in patients with
programmed death-ligand 1-positive nasopharyngeal carcinoma:
Results of the KEYNOTE-028 study. J Clin Oncol. 35:4050–4056. 2017.
View Article : Google Scholar
|
|
28
|
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong
WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, et al:
Pembrolizumab monotherapy versus chemotherapy in
platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
(KEYNOTE-122): An open-label, randomized, phase III trial. Ann
Oncol. 34:251–261. 2023. View Article : Google Scholar
|
|
29
|
Shi Y, Qin X, Peng X, Zeng A, Li J, Chen
C, Qiu S, Pan S, Zheng Y, Cai J, et al: Efficacy and safety of
KL-A167 in previously treated recurrent or metastatic
nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 study.
Lancet Reg Health West Pac. 31:1006172022.
|
|
30
|
Li Y, Min Y, Wei Z, Liu Z, Pei Y, Yang Y,
Gao K, Song G, Xu S, He S, et al: Metastatic sites of baseline as
predictors in recurrent or metastatic nasopharyngeal carinoma
treated with PD-L1 inhibitor: A secondary analysis of multicenter,
single-arm, phase II study (KL-A167). Cancer Immunol Immunother.
74:722025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Min Y, Wei Z, Liu Z, Pei Y, Yang Y,
Gao K, Song G, Xu S, He S, et al: Correction: Metastatic sites of
baseline as predictors in recurrent or metastatic nasopharyngeal
carinoma treated with PD-L1 inhibitor: A secondary analysis of
multicenter, single-arm, phase II study (KL-A167). Cancer Immunol
Immunother. 74:3222025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Dai Z, Wu W, Wang Z, Zhang N,
Zhang L, Zeng WJ, Liu Z and Cheng Q: Regulatory mechanisms of
immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer
Res. 40:1842021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lim DWT, Kao HF, Suteja L, Li CH, Quah HS,
Tan DSW, Tan SH, Tan EH, Tan WL, Lee JN, et al: Clinical efficacy
and biomarker analysis of dual PD-1/CTLA-4 blockade in
recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nat
Commun. 14:27812023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma Y, Zhou H, Luo F, Zhang Y, Zhu C, Li W,
Huang Z, Zhao J, Xue J, Zhao Y, et al: Remodeling the tumor-immune
microenvironment by anti-CTLA4 blockade enhanced subsequent
anti-PD-1 efficacy in advanced nasopharyngeal carcinoma. NPJ Precis
Oncol. 8:652024. View Article : Google Scholar
|
|
36
|
Jiang Y, Bei W, Wang L, Lu N, Xu C, Liang
H, Ke L, Ye Y, He S, Dong S, et al: Efficacy and safety of
cadonilimab (PD-1/CTLA-4 bispecific) in combination with
chemotherapy in anti-PD-1-resistant recurrent or metastatic
nasopharyngeal carcinoma: A single-arm, open-label, phase 2 trial.
BMC Med. 23:1522025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen QY, Guo SS, Luo Y, Qu S, Wu DH, Chen
XZ, Chen DP, Qin XT, Lin Q, Jin F, et al: Efficacy and safety of
cadonilimab in previously treated recurrent or metastatic
nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter
study. Oral Oncol. 151:1067232024. View Article : Google Scholar
|
|
38
|
Cao F, Li Y, Fang Q, Lin R, Zhao Z, Xu P,
Yan H, Zhang X, Jiang K, Zhou J, et al: Cadonilimab (a PD-1/CTLA-4
bispecific antibody) plus neoadjuvant chemotherapy in locally
advanced head and neck squamous cell carcinoma: A phase II clinical
trial. Clin Cancer Res. 31:3876–3885. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Meij P, Leen A, Rickinson AB, Verkoeijen
S, Vervoort MBHJ, Bloemena E and Middeldorp JM: Identification and
prevalence of CD8(+) T-cell responses directed against Epstein-Barr
virus-encoded latent membrane protein 1 and latent membrane protein
2. Int J Cancer. 99:93–99. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Comoli P, Pedrazzoli P, Maccario R, Basso
S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C,
Perotti C, et al: Cell therapy of stage IV nasopharyngeal carcinoma
with autologous Epstein-Barr virus-targeted cytotoxic T
lymphocytes. J Clin Oncol. 23:8942–8949. 2005. View Article : Google Scholar
|
|
41
|
Chia WK, Teo M, Wang WW, Lee B, Ang SF,
Tai WM, Chee CL, Ng J, Kan R, Lim WT, et al: Adoptive T-cell
transfer and chemotherapy in the first-line treatment of metastatic
and/or locally recurrent nasopharyngeal carcinoma. Mol Ther.
22:132–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Toh HC, Yang MH, Wang HM, Hsieh CY,
Chitapanarux I, Ho KF, Hong RL, Ang MK, Colevas AD, Sirachainan E,
et al: Gemcitabine, carboplatin, and Epstein-Barr virus-specific
autologous cytotoxic T lymphocytes for recurrent or metastatic
nasopharyngeal carcinoma: VANCE, an international randomized phase
III trial. Ann Oncol. 35:1181–1190. 2024. View Article : Google Scholar
|
|
43
|
Looi CK, Loo EM, Lim HC, Chew YL, Chin KY,
Cheah SC, Goh BH and Mai CW: Revolutionizing the treatment for
nasopharyngeal cancer: The impact, challenges and strategies of
stem cell and genetically engineered cell therapies. Front Immunol.
15:14845352024. View Article : Google Scholar
|
|
44
|
Jackson HJ, Rafiq S and Brentjens RJ:
Driving CAR T-cells forward. Nat Rev Clin Oncol. 13:370–383. 2016.
View Article : Google Scholar
|
|
45
|
Zhang H, Yang L, Wang T and Li Z: NK
cell-based tumor immunotherapy. Bioact Mater. 31:63–86.
2023.PubMed/NCBI
|
|
46
|
Lim CM, Liou A, Poon M, Koh LP, Tan LK,
Loh KS, Petersson BF, Ting E, Campana D, Goh BC and Shimasaki N:
Phase I study of expanded natural killer cells in combination with
cetuximab for recurrent/metastatic nasopharyngeal carcinoma. Cancer
Immunol Immunother. 71:2277–2286. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan
CX and Zhu Z: CAR race to cancer immunotherapy: From CAR T, CAR NK
to CAR macrophage therapy. J Exp Clin Cancer Res. 41:1192022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liao Y, Yan J, Beri NR, Giulino-Roth L,
Cesarman E and Gewurz BE: Germinal center cytokine driven
epigenetic control of Epstein-Barr virus latency gene expression.
PLoS Pathog. 20:e10119392024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sayour EJ, Boczkowski D, Mitchell DA and
Nair SK: Cancer mRNA vaccines: Clinical advances and future
opportunities. Nat Rev Clin Oncol. 21:489–500. 2024. View Article : Google Scholar
|
|
50
|
Guo M, Duan X, Peng X, Jin Z, Huang H,
Xiao W, Zheng Q, Deng Y, Fan N, Chen K and Song X: A lipid-based
LMP2-mRNA vaccine to treat nasopharyngeal carcinoma. Nano Res.
16:5357–5367. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xiang Y, Tian M, Huang J, Li Y, Li G, Li
X, Jiang Z, Song X and Ma X: LMP2-mRNA lipid nanoparticle
sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T
cell exhaustion. J Nanobiotechnology. 21:3242023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang K, Lin XJ, Hu JC, Xia TY, Xu FP,
Huang JD and Zhou N: Epstein-Barr virus mRNA vaccine synergizes
with NK cells to enhance nasopharyngeal carcinoma eradication in
humanized mice. Mol Ther Oncol. 33:2009862025. View Article : Google Scholar
|
|
53
|
Li H, Min L, Du H, Wei X and Tong A:
Cancer mRNA vaccines: Clinical application progress and challenges.
Cancer Lett. 625:2177522025. View Article : Google Scholar
|
|
54
|
Liu Q, Yu S, Zhao W, Qin S, Chu Q and Wu
K: EGFR-TKIs resistance via EGFR-independent signaling pathways.
Mol Cancer. 17:532018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Roskoski R Jr: Small molecule inhibitors
targeting the EGFR/ErbB family of protein-tyrosine kinases in human
cancers. Pharmacol Res. 139:395–411. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
London M and Gallo E: Epidermal growth
factor receptor (EGFR) involvement in epithelial-derived cancers
and its current antibody-based immunotherapies. Cell Biol Int.
44:1267–1282. 2020. View Article : Google Scholar
|
|
57
|
Li X, Lian Z, Wang S, Xing L and Yu J:
Interactions between EGFR and PD-1/PD-L1 pathway: Implications for
treatment of NSCLC. Cancer Lett. 418:1–9. 2018. View Article : Google Scholar
|
|
58
|
Hong X, Wang G, Xu G, Shi W, Wang T, Rong
Z and Mo C: Prognostic value of EGFR and p-EGFR in nasopharyngeal
carcinoma: A systematic review and meta-analysis. Medicine
(Baltimore). 101:e285072022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chan ATC, Hsu MM, Goh BC, Hui EP, Liu TW,
Millward MJ, Hong RL, Whang-Peng J, Ma BBY, To KF, et al:
Multicenter, phase II study of cetuximab in combination with
carboplatin in patients with recurrent or metastatic nasopharyngeal
carcinoma. J Clin Oncol. 23:3568–3576. 2005. View Article : Google Scholar
|
|
60
|
Ma BBY, Kam MKM, Leung SF, Hui EP, King
AD, Chan SL, Mo F, Loong H, Yu BKH, Ahuja A and Chan ATC: A phase
II study of concurrent cetuximab-cisplatin and intensity-modulated
radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Ann Oncol. 23:1287–1292. 2012. View Article : Google Scholar
|
|
61
|
Zhu Q, Duan XB, Hu H, You R, Xia TL, Yu T,
Xiang T and Chen MY: EBV-induced upregulation of CD55 reduces the
efficacy of cetuximab treatment in nasopharyngeal carcinoma. J
Transl Med. 22:11112024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Qu L, Wang JH, Du JX, Kang P, Niu XQ and
Yin LZ: Use of nimotuzumab combined with cisplatin in treatment of
nasopharyngeal carcinoma and its effect on expressions of VEGF and
MMP-2. Clin Transl Oncol. 23:1342–1349. 2021. View Article : Google Scholar
|
|
63
|
Zhu Y, Yang S, Zhou S, Yang J, Qin Y, Gui
L, Shi Y and He X: Nimotuzumab plus platinum-based chemotherapy
versus platinum-based chemotherapy alone in patients with recurrent
or metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol.
12:17588359209537382020. View Article : Google Scholar
|
|
64
|
Zhao C, Miao J, Shen G, Li J, Shi M, Zhang
N, Hu G, Chen X, Hu X, Wu S, et al: Anti-epidermal growth factor
receptor (EGFR) monoclonal antibody combined with cisplatin and
5-fluorouracil in patients with metastatic nasopharyngeal carcinoma
after radical radiotherapy: A multicentre, open-label, phase II
clinical trial. Ann Oncol. 30:637–643. 2019. View Article : Google Scholar
|
|
65
|
Zou Q, Cao Y, Lai Y, Fang Y, Zhang Y, Liu
P, Lu L, Wu H, Huang T, Su N, et al: Nimotuzumab combined with
docetaxel and cisplatin as first-line treatment for patients with
recurrent or metastatic nasopharyngeal carcinoma: A multicenter,
phase 2 trial. BMC Med. 23:2642025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W,
Liao W, Xu Z, Zhang W, Zhao HY, Wei X, et al: Evaluation of safety
of treatment with anti-epidermal growth factor receptor antibody
drug conjugate MRG003 in patients with advanced solid tumors: A
phase 1 nonrandomized clinical trial. JAMA Oncol. 8:1042–1046.
2022. View Article : Google Scholar
|
|
67
|
Xue L, Han Y, Zhang Q, Li X, Fang M, Zhong
L, Wang S, Liu Y, Zhang S and Guo Y: 939P Efficacy and safety of a
novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell
carcinoma of the head and neck patients. Ann Oncol. 34 (Suppl
2):S5902023. View Article : Google Scholar
|
|
68
|
Xu RH, Ruan D, Han F, Zhou Y, Wang F, Tang
LQ, Li Z, Chen C, Lin J, Liu F, et al: 402O Preliminary results of
phase II study to evaluate safety and efficacy of combination
pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC)
MRG003 in recurrent or metastatic nasopharyngeal carcinoma
(R/M-NPC). Ann Oncol. 35 (Suppl 4):S15542024. View Article : Google Scholar
|
|
69
|
Han F, Wang X, Xiang Y, Tang LQ, Qu S, Shu
X, Zhang P, Qiu S, Zhou Y, Guo Y, et al: Becotatug vedotin vs.
chemotherapy in pre-heavily treated advanced nasopharyngeal
carcinoma: A randomized, controlled, multicenter, open-label study.
J Clin Oncol. 43 (17 Suppl):LBA60052025. View Article : Google Scholar
|
|
70
|
Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang
Y, Fang W, Guo Y, Han Y, Yang K, et al: BL-B01D1, a first-in-class
EGFR-HER3 bispecific antibody-drug conjugate, in patients with
locally advanced or metastatic solid tumours: A first-in-human,
open-label, multicentre, phase 1 study. Lancet Oncol. 25:901–911.
2024. View Article : Google Scholar
|
|
71
|
Jiménez-Labaig P, Rullan A, Hernando-Calvo
A, Llop S, Bhide S, O'Leary B, Braña I and Harrington KJ: A
systematic review of antibody-drug conjugates and bispecific
antibodies in head and neck squamous cell carcinoma and
nasopharyngeal carcinoma: Charting the course of future therapies.
Cancer Treat Rev. 128:1027722024. View Article : Google Scholar
|
|
72
|
Yang Y, Zhou H, Tang L, Qiu S, Han Y, Ji
D, Chen X, Lei F, Qu S, Deng B, et al: Izalontamab brengitecan, an
EGFR and HER3 bispecific antibody-drug conjugate, versus
chemotherapy in heavily pretreated recurrent or metastatic
nasopharyngeal carcinoma: A multicentre, randomised, open-label,
phase 3 study in China. Lancet. 406:2235–2243. 2025. View Article : Google Scholar
|
|
73
|
Wang H, Fan S, Zhan Y, Xu Y, Du Y, Luo J,
Zang H, Peng S and Wang W: Targeting EGFR-binding protein SLC7A11
enhancing antitumor immunity of T cells via inducing MHC-I antigen
presentation in nasopharyngeal carcinoma. C Cell Death Dis.
16:212025. View Article : Google Scholar
|
|
74
|
Pollack BP: EGFR inhibitors, MHC
expression and immune responses: Can EGFR inhibitors be used as
immune response modifiers? Oncoimmunology. 1:71–74. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Madeddu C, Donisi C, Liscia N, Lai E,
Scartozzi M and Macciò A: EGFR-mutated non-small cell lung cancer
and resistance to immunotherapy: Role of the tumor
microenvironment. Int J Mol Sci. 23:64892022. View Article : Google Scholar
|
|
77
|
Ma BBY, Lui VWY, Poon FF, Wong SCC, To KF,
Wong E, Chen H, Lo KW, Tao Q, Chan ATC, et al: Preclinical activity
of gefitinib in non-keratinizing nasopharyngeal carcinoma cell
lines and biomarkers of response. Invest New Drugs. 28:326–333.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chua DT, Wei WI, Wong MP, Sham JS,
Nicholls J and Au GK: Phase II study of gefitinib for the treatment
of recurrent and metastatic nasopharyngeal carcinoma. Head Neck.
30:863–867. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Isomoto K, Haratani K, Hayashi H, Shimizu
S, Tomida S, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, et al:
Impact of EGFR-TKI treatment on the tumor immune microenvironment
in EGFR mutation-positive non-small cell lung cancer. Clin Cancer
Res. 26:2037–2046. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li
K, Nishiyama A, Arai S, Yano S and Wang W: EGFR-TKI resistance
promotes immune escape in lung cancer via increased PD-L1
expression. Mol Cancer. 18:1652019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ferrara N: VEGF and intraocular
neovascularization: From discovery to therapy. Transl Vis Sci
Technol. 5:102016. View Article : Google Scholar
|
|
82
|
Ghalehbandi S, Yuzugulen J, Pranjol MZI
and Pourgholami MH: The role of VEGF in cancer-induced angiogenesis
and research progress of drugs targeting VEGF. Eur J Pharmacol.
949:1755862023. View Article : Google Scholar
|
|
83
|
Apte RS, Chen DS and Ferrara N: VEGF in
signaling and disease: Beyond discovery and development. Cell.
176:1248–1264. 2019. View Article : Google Scholar
|
|
84
|
Htet H, Anaghan JRJ, Jaiprakash H, Burud
IAS, Subramaniam T, Iezhitsa I and Agarwal R: Efficacy and safety
of molecular targeted therapies in nasopharyngeal carcinoma: A
network meta-analysis. BMC Cancer. 25:1102025. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yang J, Yan J and Liu B: Targeting
VEGF/VEGFR to modulate antitumor immunity. Front Immunol.
9:9782018. View Article : Google Scholar
|
|
86
|
Allen E, Jabouille A, Rivera LB,
Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D,
Michael IP and Bergers G: Combined antiangiogenic and anti-PD-L1
therapy stimulates tumor immunity through HEV formation. Sci Transl
Med. 9:eaak96792017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang L, Lin Y, Hu L, Wang Y, Hu C,
Shangguan X, Tang S, Chen J, Hu P, Chen ZS, et al: Transient
intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in
cancer cells inspires long-term T cell activation and infiltration
to combat tumor and inhibit cancer metastasis. Mol Cancer.
24:1192025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hack SP, Zhu AX and Wang Y: Augmenting
anticancer immunity through combined targeting of angiogenic and
PD-1/PD-L1 pathways: Challenges and opportunities. Front Immunol.
11:5988772020. View Article : Google Scholar
|
|
89
|
Schmittnaegel M, Rigamonti N, Kadioglu E,
Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi
CH, Laoui D and De Palma M: Dual angiopoietin-2 and VEGFA
inhibition elicits antitumor immunity that is enhanced by PD-1
checkpoint blockade. Sci Transl Med. 9:eaak96702017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao
Y, Chen Y and Guo QL: Endostar, a novel recombinant human
endostatin, exerts antiangiogenic effect via blocking VEGF-induced
tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem
Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y,
Chen J, Hu X, Zhou Q, Wang Y, et al: Recombinant human endostatin
normalizes tumor vasculature and enhances radiation response in
xenografted human nasopharyngeal carcinoma models. PLoS One.
7:e346462012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Jin T, Li B and Chen XZ: A phase II trial
of Endostar combined with gemcitabine and cisplatin chemotherapy in
patients with metastatic nasopharyngeal carcinoma (NCT01612286).
Oncol Res. 21:317–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li Y, Tian Y, Jin F, Wu W, Long J, Ouyang
J and Zhou Y: A phase II multicenter randomized controlled trial to
compare standard chemoradiation with or without recombinant human
endostatin injection (Endostar) therapy for the treatment of
locally advanced nasopharyngeal carcinoma: Long-term outcomes
update. Curr Probl Cancer. 44:1004922020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Xu L, Li D, Ji J, Chen Z, Tang X, Chen D,
Li X, Bao D, Yan F, Pang Y, et al: Recombinant human endostatin
injection (Endostar) combined with PF chemotherapy and sequential
intensity-modulated radiotherapy is tolerable and improves
prognosis of locally advanced nasopharyngeal carcinoma: A
randomized, open, multicenter phase II clinical study. Am J Cancer
Res. 12:4622–4636. 2022.PubMed/NCBI
|
|
96
|
Zhang Y, Zou Q, Zhao B, Su N, Li Z, Wang
X, Liu P, Tian X, Fang X, Cai J, et al: Toripalimab plus anlotinib
in patients with recurrent or metastatic nasopharyngeal carcinoma:
A multicenter, single-arm phase 2 trial (TORAL). Cell Rep Med.
5:1018332024. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin
DF, Liu LT, Luo DH, Li YF, Deng SW, et al: Camrelizumab combined
with apatinib in patients with first-line platinum-resistant or
PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal
carcinoma: A single-arm, phase 2 trial. Nat Commun. 14:48932023.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mo Y, Pan Y, Zhang B, Zhang J, Su Y, Liu
Z, Luo M, Qin G, Kong X, Zhang R, et al: Apatinib combined with
camrelizumab in the treatment of recurrent/metastatic
nasopharyngeal carcinoma: A prospective multicenter phase II study.
Front Immunol. 14:12984182024. View Article : Google Scholar
|
|
99
|
Liang H, Jiang YF, Liu GY, Wang L, Wang
JW, Lu N, Xia WX, Ke LR, Ye YF, Duan JL, et al: Camrelizumab and
apatinib plus induction chemotherapy and concurrent
chemoradiotherapy in stage N3 nasopharyngeal carcinoma: A phase 2
clinical trial. Nat Commun. 15:10292024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chong WQ, Low JL, Tay JK, Le TBU, Goh GSQ,
Sooi K, Teo HL, Cheo SW, Wong RTX, Samol J, et al: Pembrolizumab
with or without bevacizumab in platinum-resistant recurrent or
metastatic nasopharyngeal carcinoma: A randomised, open-label,
phase 2 trial. Lancet Oncol. 26:175–186. 2025. View Article : Google Scholar
|
|
101
|
Tang LQ, Liu SL, Yang MH, Wang HC, Zhou
YJ, Yang KY, Li Q, Hui M, Chen XZ, Leu YS, et al: GFH018 and
toripalimab combination therapy for previously treated recurrent or
metastatic nasopharyngeal carcinoma: Results from a phase Ib/II
study. Clin Cancer Res. 31:3424–3432. 2025. View Article : Google Scholar : PubMed/NCBI
|
